Scarica l'app Stockscreener
40.72
0.67%
0.27
Dopo l'orario di chiusura:
41.50
0.78
+1.92%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$40.45
Aprire:
$39.69
Volume 24 ore:
270.26K
Relative Volume:
0.73
Capitalizzazione di mercato:
$1.94B
Reddito:
$264.38M
Utile/perdita netta:
$-109.16M
Rapporto P/E:
-9.479
EPS:
-4.2958
Flusso di cassa netto:
$-39.22M
1 W Prestazione:
+4.25%
1M Prestazione:
+3.72%
6M Prestazione:
+57.59%
1 anno Prestazione:
+35.73%
Intervallo 1D:
$38.16
$41.00
Intervallo di 1 settimana:
$38.16
$41.15
Portata 52W:
$23.14
$45.23
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum Pharmaceuticals (MIRM) Scheduled to Post Earnings on Tuesday - MarketBeat
AlphaCentric Advisors LLC Decreases Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - StockTitan
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt? - Simply Wall St
(MIRM) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know - MSN
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting - BioSpace
LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by Analysts - MarketBeat
Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth - Insider Monkey
How to Take Advantage of moves in (MIRM) - Stock Traders Daily
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Leerink Partners Boosts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $49.00 - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $49.00 at Leerink Partners - MarketBeat
Mirum PharmaEyeing 50% Annual Growth In 2023 - RTTNews
Mirum’s liver disease drug candidate gets FDA breakthrough designation - MSN
(MIRM) Trading Advice - Stock Traders Daily
H.C. Wainwright maintains Buy rating on Mirum shares as enrollment for key study continues - Investing.com Canada
Analyst Expectations For Mirum Pharmaceuticals's Future - Benzinga
Mirum Pharmaceuticals (NASDAQ:MIRM) Given "Buy" Rating at HC Wainwright - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
FDA grants breakthrough status to Mirum's PBC drug By Investing.com - Investing.com Canada
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis - BioSpace
Mirum Pharmaceuticals' Volixibat Gets Breakthrough Therapy Designation from FDA - MarketWatch
Millennium Management LLC Has $9.08 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Abacus & Mirum Partner For The Commercialization Of LIVMARLI In Nordic Markets - Contract Pharma
Cantor Fitzgerald Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Overweight Recommendation - MSN
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Clearbridge Investments LLC - MarketBeat
Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish (MIRM) - Seeking Alpha
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Squarepoint Ops LLC - MarketBeat
Alagille Syndrome Market Forecasted to Surge in Coming Years, - openPR
Exploring High Growth Tech Stocks In The US October 2024 - Simply Wall St
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading 5.9% Higher - MarketBeat
(MIRM) Investment Report - Stock Traders Daily
Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Target Price at $56.27 - MarketBeat
Mirum Pharmaceuticals' SWOT analysis: liver disease specialist's stock poised for growth - Investing.com
Axa S.A. Sells 167,794 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Profund Advisors LLC Has $445,000 Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
XTX Topco Ltd Invests $521,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) - MarketBeat
Micron Technology Inc. stock rises Tuesday, outperforms market - MarketWatch
Farallon Capital Management LLC Takes Position in Merus (NASDAQ:MRUS) - Defense World
Market Insight: Merus N.V (MRUS)’s Notable Drop, Closing at 47.77 - The Dwinnex
Great Point Partners LLC Increases Stake in Merus (NASDAQ:MRUS) - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) pulls back 3.7% this week, but still delivers shareholders stellar 31% CAGR over 5 years - Simply Wall St
Logos Global Management LP Invests $50.29 Million in Merus (NASDAQ:MRUS) - Defense World
Market Resilience: Moderna Inc (MRNA) Finishes Weak at 64.14, Down -2.36 - The Dwinnex
Summit Trail Advisors LLC Buys 403 Shares of Moderna, Inc. (NASDAQ:MRNA) - Defense World
What the Options Market Tells Us About Micron Technology - Benzinga
Micron Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Market Recap: MaxLinear Inc (MXL)’s Positive Momentum, Closing at 14.31 - The Dwinnex
XTX Topco Ltd Sells 1,569 Shares of Micron Technology, Inc. (NASDAQ:MU) - Defense World
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):